{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:55:44Z","timestamp":1780070144605,"version":"3.54.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Erectile dysfunction (ED) is frequently underreported in men suffering from prolactinomas and can be challenging to manage. Both dopamine agonists (DAs) and transsphenoidal surgery (TSS) correct hyperprolactinemia and restore gonadal function. However, there is scarce data regarding their effectiveness in correcting ED over the long term.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study is a retrospective single-center comparative cohort study analyzing men diagnosed with prolactinomas, both with and without confirmed erectile dysfunction (ED) at diagnosis. Independent risk factors for persistent ED over the long term were examined using multivariate logistic regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 39 men with lactotroph adenomas, ED was one of the presenting symptoms in 22 (56%). The mean age at diagnosis was 45\u2009\u00b1\u200912\u00a0years. Surgery was the primary treatment in 6 (27%) ED patients and 8 (47%) non-ED patients. After a mean follow-up of 74\u2009\u00b1\u200948\u00a0months, remission from hyperprolactinemia was achieved in the majority (76%) of men: 71% in the non-ED cohort and 81% in the ED group (<jats:italic>p<\/jats:italic>\u2009=\u20090.70), regardless of the primary treatment strategy (surgical 84% versus medical 72%, <jats:italic>p<\/jats:italic>\u2009=\u20090.46). Long-term remission of ED was noted in 16 (73%) patients. Interestingly, high baseline BMI levels emerged as potential risk factors for persistent ED over the long term (OR 1.4, 95%CI 1.0\u20131.9; <jats:italic>p<\/jats:italic>\u2009=\u20090.04), while neither the initial adenoma size nor the primary treatment strategy (i.e., TSS vs. DAs) reached statistical significance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Correcting hyperprolactinemia and its associated hypogonadism significantly improves ED in the majority of men with prolactinomas over the long term, regardless of the primary treatment strategy employed. In addition to addressing endocrine deficiencies, the early initiation of weight control programs may be considered for men with lactotroph adenomas and ED. Although our study suggests an association between BMI and the risk of persistent ED, further research is needed to establish any causal relationships.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00701-024-06213-9","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T20:02:29Z","timestamp":1722456149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma"],"prefix":"10.1007","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-688X","authenticated-orcid":false,"given":"Lukas","family":"Andereggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit A.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Musahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Kobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus M.","family":"Luedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Roethlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"6213_CR1","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/andr.12878","volume":"8","author":"L Afferi","year":"2020","unstructured":"Afferi L, Pannek J, Louis Burnett A, Razaname C, Tzanoulinou S, Bobela W, da Silva RAF, Sturny M, Stergiopulos N, Cornelius J, Moschini M, Iselin C, Salonia A, Mattei A, Mordasini L (2020) Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature. Andrology 8:1660\u20131673. https:\/\/doi.org\/10.1111\/andr.12878","journal-title":"Andrology"},{"key":"6213_CR2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae383","author":"L Andereggen","year":"2024","unstructured":"Andereggen L, Christ E (2024) Letter to the Editor from Andereggen and Christ: Clinical characteristics and outcomes of prolactinomas in children and adolescents: A large retrospective cohort study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae383","journal-title":"J Clin Endocrinol Metab"},{"key":"6213_CR3","doi-asserted-by":"publisher","first-page":"1371468","DOI":"10.3389\/fendo.2024.1371468","volume":"15","author":"L Andereggen","year":"2024","unstructured":"Andereggen L, Christ E (2024) Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. Front Endocrinol (Lausanne) 15:1371468. https:\/\/doi.org\/10.3389\/fendo.2024.1371468","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6213_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12020-016-1115-2","volume":"55","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55:223\u2013230. https:\/\/doi.org\/10.1007\/s12020-016-1115-2","journal-title":"Endocrine"},{"key":"6213_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595\u2013602. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059","journal-title":"World Neurosurg"},{"key":"6213_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12020-020-02557-1","volume":"72","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Christ E (2021) Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine 72:216\u2013222. https:\/\/doi.org\/10.1007\/s12020-020-02557-1","journal-title":"Endocrine"},{"key":"6213_CR7","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, Widmer HR, Beck J, Mariani L, Christ E (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11:5122. https:\/\/doi.org\/10.1038\/s41598-021-84606-x","journal-title":"Sci Rep"},{"key":"6213_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurad.2019.05.004","volume":"48","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Gralla J, Schroth G, Mordasini P, Andres RH, Widmer HR, Luedi MM, Kellner F, Beck J, Mariani L, Ozdoba C, Christ E (2021) Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing\u2019s syndrome. J Neuroradiol 48:10\u201315. https:\/\/doi.org\/10.1016\/j.neurad.2019.05.004","journal-title":"J Neuroradiol"},{"key":"6213_CR9","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s00701-021-04830-2","volume":"163","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Mariani L, Beck J, Andres RH, Gralla J, Luedi MM, Weis J, Christ E (2021) Lateral one-third gland resection in Cushing patients with failed adenoma identification leads to low remission rates: long-term observations from a small, single-center cohort. Acta Neurochir (Wien) 163:3161\u20133169. https:\/\/doi.org\/10.1007\/s00701-021-04830-2","journal-title":"Acta Neurochir (Wien)"},{"key":"6213_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01569-6","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, El-Koussy M, Widmer HR, Beck J, Mariani L, Seiler RW, Christ E (2021) First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-021-01569-6","journal-title":"J Endocrinol Invest"},{"key":"6213_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100258","volume":"24","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, Gralla J, Schubert GA, Beck J, Mariani L, Christ E (2021) Impact of primary medical or surgical therapy on prolactinoma patients\u2019 BMI and metabolic profile over the long-term. J Clin Transl Endocrinol 24:100258. https:\/\/doi.org\/10.1016\/j.jcte.2021.100258","journal-title":"J Clin Transl Endocrinol"},{"key":"6213_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.967407","volume":"10","author":"L Andereggen","year":"2023","unstructured":"Andereggen L, Tortora A, Schubert GA, Musahl C, Frey J, Luedi MM, Mariani L, Beck J, Christ E (2023) Prolactinomas in adolescent and elderly patients-A comparative long-term analysis. Front Surg 10:967407. https:\/\/doi.org\/10.3389\/fsurg.2023.967407","journal-title":"Front Surg"},{"key":"6213_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00701-024-06058-2","volume":"166","author":"L Andereggen","year":"2024","unstructured":"Andereggen L, Gralla J, Christ E (2024) The diagnostic yield of inferior petrosal sinus sampling in Cushing syndrome in the era of ovine CRH shortage. Acta Neurochir (Wien) 166:167. https:\/\/doi.org\/10.1007\/s00701-024-06058-2","journal-title":"Acta Neurochir (Wien)"},{"key":"6213_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/0003-4819-139-3-200308050-00005","volume":"139","author":"CG Bacon","year":"2003","unstructured":"Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB (2003) Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 139:161\u2013168. https:\/\/doi.org\/10.7326\/0003-4819-139-3-200308050-00005","journal-title":"Ann Intern Med"},{"key":"6213_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","volume":"23","author":"V Bonert","year":"2020","unstructured":"Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23:307\u2013313. https:\/\/doi.org\/10.1007\/s11102-020-01039-x","journal-title":"Pituitary"},{"key":"6213_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.ijir.3901043","volume":"15","author":"J Buvat","year":"2003","unstructured":"Buvat J (2003) Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 15:373\u2013377. https:\/\/doi.org\/10.1038\/sj.ijir.3901043","journal-title":"Int J Impot Res"},{"key":"6213_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000180094","volume":"22","author":"J Buvat","year":"1985","unstructured":"Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie JC, Racadot A, Fossati P (1985) Hyperprolactinemia and sexual function in men. Horm Res 22:196\u2013203. https:\/\/doi.org\/10.1159\/000180094","journal-title":"Horm Res"},{"key":"6213_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1530\/EC-19-0286","volume":"8","author":"S Byberg","year":"2019","unstructured":"Byberg S, Futtrup J, Andreassen M, Krogh J (2019) Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect 8:1395\u20131404. https:\/\/doi.org\/10.1530\/EC-19-0286","journal-title":"Endocr Connect"},{"key":"6213_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2605.1996.tb00434.x","volume":"19","author":"C Carani","year":"1996","unstructured":"Carani C, Granata AR, Fustini MF, Marrama P (1996) Prolactin and testosterone: their role in male sexual function. Int J Androl 19:48\u201354. https:\/\/doi.org\/10.1111\/j.1365-2605.1996.tb00434.x","journal-title":"Int J Androl"},{"key":"6213_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265\u2013273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol"},{"key":"6213_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol 79:845\u2013852. https:\/\/doi.org\/10.1111\/cen.12204","journal-title":"Clin Endocrinol"},{"key":"6213_CR22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023\u20132033. https:\/\/doi.org\/10.1056\/NEJMoa022657","journal-title":"N Engl J Med"},{"key":"6213_CR23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M (2009) Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 6:1457\u20131466. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x","journal-title":"J Sex Med"},{"key":"6213_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3275\/8063","volume":"35","author":"G Corona","year":"2012","unstructured":"Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Maggi M (2012) Testosterone and cardiovascular risk in patients with erectile dysfunction. J Endocrinol Invest 35:809\u2013816. https:\/\/doi.org\/10.3275\/8063","journal-title":"J Endocrinol Invest"},{"key":"6213_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40618-020-01257-x","volume":"43","author":"G Corona","year":"2020","unstructured":"Corona G, Sansone A, Pallotti F, Ferlin A, Pivonello R, Isidori AM, Maggi M, Jannini EA (2020) People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. J Endocrinol Invest 43:1391\u20131408. https:\/\/doi.org\/10.1007\/s40618-020-01257-x","journal-title":"J Endocrinol Invest"},{"key":"6213_CR26","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-21-0977","volume":"186","author":"R Cozzi","year":"2022","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M, Ciccarelli E, De Marinis L, De Menis E, Faustini Fustini M, Grimaldi F, Lania A, Lasio G, Logoluso F, Losa M, Maffei P, Milani D, Poggi M, Zini M, Katznelson L, Luger A, Poiana C (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol 186:P1\u2013P33. https:\/\/doi.org\/10.1530\/EJE-21-0977","journal-title":"Eur J Endocrinol"},{"key":"6213_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.21037\/tau.2016.09.01","volume":"5","author":"M Crawford","year":"2016","unstructured":"Crawford M, Kennedy L (2016) Testosterone replacement therapy: role of pituitary and thyroid in diagnosis and treatment. Transl Androl Urol 5:850\u2013858. https:\/\/doi.org\/10.21037\/tau.2016.09.01","journal-title":"Transl Androl Urol"},{"key":"6213_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","volume":"20","author":"M De Rosa","year":"2003","unstructured":"De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B, Lombardi G, Colao A (2003) Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 20:75\u201382. https:\/\/doi.org\/10.1385\/ENDO:20:1-2:75","journal-title":"Endocrine"},{"key":"6213_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77\u201384. https:\/\/doi.org\/10.1530\/eje.0.1470077","journal-title":"Eur J Endocrinol"},{"key":"6213_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM dos Santos Silva","year":"2011","unstructured":"dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 19:800\u2013805. https:\/\/doi.org\/10.1038\/oby.2010.150","journal-title":"Obesity (Silver Spring)"},{"key":"6213_CR31","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1001\/jama.291.24.2978","volume":"291","author":"K Esposito","year":"2004","unstructured":"Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D\u2019Andrea F, D\u2019Armiento M, Giugliano D (2004) Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291:2978\u20132984. https:\/\/doi.org\/10.1001\/jama.291.24.2978","journal-title":"JAMA"},{"key":"6213_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1515\/JPEM.2005.18.9.921","volume":"18","author":"F Galluzzi","year":"2005","unstructured":"Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels\u2013long-term follow-up in childhood. Journal of Pediatric Endocrinol Metab\u202f: JPEM 18:921\u2013924","journal-title":"Journal of Pediatric Endocrinol Metab : JPEM"},{"key":"6213_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","volume":"48","author":"Y Greenman","year":"1998","unstructured":"Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547\u2013553. https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00403.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"6213_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23:45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"6213_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.810219","volume":"13","author":"M Huber","year":"2022","unstructured":"Huber M, Luedi MM, Schubert GA, Musahl C, Tortora A, Frey J, Beck J, Mariani L, Christ E, Andereggen L (2022) Machine learning for outcome prediction in first-line surgery of prolactinomas. Front Endocrinol (Lausanne) 13:810219. https:\/\/doi.org\/10.3389\/fendo.2022.810219","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6213_CR36","doi-asserted-by":"publisher","first-page":"1363431","DOI":"10.3389\/fsurg.2024.1363431","volume":"11","author":"M Huber","year":"2024","unstructured":"Huber M, Luedi MM, Schubert GA, Musahl C, Tortora A, Frey J, Beck J, Mariani L, Christ E, Andereggen L (2024) Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility. Front Surg 11:1363431. https:\/\/doi.org\/10.3389\/fsurg.2024.1363431","journal-title":"Front Surg"},{"key":"6213_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.ijir.3900675","volume":"13","author":"AM Johri","year":"2001","unstructured":"Johri AM, Heaton JP, Morales A (2001) Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 13:176\u2013182. https:\/\/doi.org\/10.1038\/sj.ijir.3900675","journal-title":"Int J Impot Res"},{"key":"6213_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524\u2013529. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02627.x","journal-title":"Clin Endocrinol"},{"key":"6213_CR39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610\u2013617. https:\/\/doi.org\/10.1227\/00006123-199310000-00008. (discussion 617\u2013618)","journal-title":"Neurosurgery"},{"key":"6213_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/oby.2003.46","volume":"11","author":"J Korner","year":"2003","unstructured":"Korner J, Lo J, Freda PU, Wardlaw SL (2003) Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res 11:311\u2013312. https:\/\/doi.org\/10.1038\/oby.2003.46","journal-title":"Obes Res"},{"key":"6213_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.ju.0000162049.95483.51","volume":"174","author":"CW Kratzik","year":"2005","unstructured":"Kratzik CW, Schatzl G, Lunglmayr G, Rucklinger E, Huber J (2005) The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 174:240\u2013243. https:\/\/doi.org\/10.1097\/01.ju.0000162049.95483.51","journal-title":"J Urol"},{"key":"6213_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40618-018-0872-6","volume":"41","author":"MI Maiorino","year":"2018","unstructured":"Maiorino MI, Bellastella G, Giugliano D, Esposito K (2018) From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. J Endocrinol Invest 41:1249\u20131258. https:\/\/doi.org\/10.1007\/s40618-018-0872-6","journal-title":"J Endocrinol Invest"},{"key":"6213_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01788-5","author":"R Mazzilli","year":"2022","unstructured":"Mazzilli R, Zamponi V, Olana S, Mikovic N, Cimadomo D, Defeudis G, Faggiano A (2022) Erectile dysfunction as a marker of endocrine and glycemic disorders. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-022-01788-5","journal-title":"J Endocrinol Invest"},{"key":"6213_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine S (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"6213_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko AS, Wohrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122:803\u2013811. https:\/\/doi.org\/10.3171\/2014.12.JNS141083","journal-title":"J Neurosurg"},{"key":"6213_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/00926230390224756","volume":"29","author":"TM Moore","year":"2003","unstructured":"Moore TM, Strauss JL, Herman S, Donatucci CF (2003) Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. J Sex Marital Ther 29:381\u2013399. https:\/\/doi.org\/10.1080\/00926230390224756","journal-title":"J Sex Marital Ther"},{"key":"6213_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/07435800.2015.1135444","volume":"41","author":"B Peric","year":"2016","unstructured":"Peric B, Kruljac I, Sundalic S, Pecina HI, Jovic A, Stefanovic M, Butorac D, Vrkljan M (2016) Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? Endocr Res 41:200\u2013206. https:\/\/doi.org\/10.3109\/07435800.2015.1135444","journal-title":"Endocr Res"},{"key":"6213_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-10-0961","volume":"164","author":"X Qu","year":"2011","unstructured":"Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G (2011) Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol\/Eur Fed Endocrine Soc 164:499\u2013504. https:\/\/doi.org\/10.1530\/EJE-10-0961","journal-title":"Eur J Endocrinol\/Eur Fed Endocrine Soc"},{"key":"6213_CR49","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95:1708\u20131716. https:\/\/doi.org\/10.1210\/jc.2009-1191","journal-title":"J Clin Endocrinol Metab"},{"key":"6213_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.ijir.3900473","volume":"12","author":"J Rehman","year":"2000","unstructured":"Rehman J, Christ G, Alyskewycz M, Kerr E, Melman A (2000) Experimental hyperprolactinemia in a rat model: alteration in centrally mediated neuroerectile mechanisms. Int J Impot Res 12:23\u201332. https:\/\/doi.org\/10.1038\/sj.ijir.3900473","journal-title":"Int J Impot Res"},{"key":"6213_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.ijir.3900859","volume":"14","author":"EL Rhoden","year":"2002","unstructured":"Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA (2002) The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 14:245\u2013250. https:\/\/doi.org\/10.1038\/sj.ijir.3900859","journal-title":"Int J Impot Res"},{"key":"6213_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319\u2013326. https:\/\/doi.org\/10.1038\/sj.ijir.3900472","journal-title":"Int J Impot Res"},{"key":"6213_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","volume":"156","author":"W Saeger","year":"2007","unstructured":"Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203\u2013216. https:\/\/doi.org\/10.1530\/eje.1.02326","journal-title":"Eur J Endocrinol"},{"key":"6213_CR54","doi-asserted-by":"publisher","unstructured":"Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 136:254\u2013258. https:\/\/doi.org\/10.4414\/smw.2006.10955","DOI":"10.4414\/smw.2006.10955"},{"key":"6213_CR55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","volume":"12","author":"A Shibli-Rahhal","year":"2009","unstructured":"Shibli-Rahhal A, Schlechte J (2009) The effects of hyperprolactinemia on bone and fat. Pituitary 12:96\u2013104. https:\/\/doi.org\/10.1007\/s11102-008-0097-3","journal-title":"Pituitary"},{"key":"6213_CR56","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12020-019-01962-5","volume":"65","author":"I Shimon","year":"2019","unstructured":"Shimon I, Hirsch D, Tsvetov G, Robenshtok E, Akirov A, Fraenkel M, Eizenberg Y, Herzberg D, Barzilay-Yoseph L, Livner A, Friedrich I, Manisterski Y, Ishay A, Yoel U, Masri H (2019) Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65:656\u2013661. https:\/\/doi.org\/10.1007\/s12020-019-01962-5","journal-title":"Endocrine"},{"key":"6213_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ncpendmet0162","volume":"2","author":"JA Wass","year":"2006","unstructured":"Wass JA (2006) When to discontinue treatment of prolactinoma? Nat Clin Pract Endocrinol Metab 2:298\u2013299. https:\/\/doi.org\/10.1038\/ncpendmet0162","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"6213_CR58","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","volume":"56","author":"R Yermus","year":"2002","unstructured":"Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol 56:562","journal-title":"Clin Endocrinol"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-024-06213-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:00:52Z","timestamp":1740171652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-024-06213-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6213"],"URL":"https:\/\/doi.org\/10.1007\/s00701-024-06213-9","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is a retrospective data project that utilized existing data to evaluate the quality of registry data. There was no patient contact for the study, and therefore, no patient consent process was conducted. The Human Research Ethics Committee of Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved the project (KEK No. 10\u201310-2006 and 8\u201311-2006). The study was conducted in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its subsequent amendments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work has not been previously published. The authors declare no conflicts of interest regarding the materials or methods used in this study or the findings reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"314"}}